Skip to content
2000
Volume 25, Issue 3
  • ISSN: 1871-529X
  • E-ISSN: 2212-4063

Abstract

The COVID-19 pandemic has revealed various long-term cardiovascular complications linked to increased inflammatory responses, particularly through Interleukin-6 (IL-6) activity. IL-6 is a major cytokine in the immune system that plays a bimodal role: it supports acute immune defense but contributes to chronic inflammation and tissue damage when dysregulated. High levels of IL-6 during and after COVID-19 are linked with poor outcomes, such as Acute Respiratory Distress Syndrome (ARDS), myocarditis, endothelial dysfunction, and thrombotic events. Chronic IL-6 signaling impairs vascular homeostasis, leading to endothelial dysfunction and increased thrombosis. Viral and cytokine-driven inflammation leads to endothelial damage caused by COVID-19. These include mechanisms that implicate the downregulation of ACE2, oxidative stress, and reduced bioavailability of nitric oxide. All these contribute to arterial stiffness, atherosclerosis, and thrombosis. It is possible to reduce the risk of heart disease by using targeted therapies, such as IL-6 inhibitors, which can help reduce inflammation. Biomarkers of endothelial health and inflammation include EPCs and CECs. Pharmacological strategies, such as RAS inhibitors and statins, may have additive effects on endothelial function, but ACE2 upregulation remains a major question. Rehabilitation and exercise-based approaches are further supportive of vascular recovery. When IL-6 activity stays high after an infection, it causes blood to clot too easily and cause thrombotic problems. This makes patients more likely to experience an ischemic stroke or pulmonary embolism. Anticoagulants and IL-6 inhibitors like tocilizumab reduce these risks. IL-6's long-term effects on the heart need to be studied more, and biomarker screening, lifestyle changes, and personalized therapies must be used to prevent heart disease as much as possible. A holistic management approach that integrates anti-inflammatory and anticoagulation strategies will significantly improve outcomes in survivors of COVID-19.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X371965250618060805
2025-06-27
2025-11-16

  • From This Site

    /content/journals/chddt/10.2174/011871529X371965250618060805
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ToblerD.L. PruzanskyA.J. NaderiS. AmbrosyA.P. SladeJ.J. Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician.Curr. Atheroscler Rep202224756357010.1007/s11883‑022‑01032‑835507278
     [Google Scholar]
  2. ChenL.Y.C. HoilandR.L. StukasS. WellingtonC.L. SekhonM.S. Assessing the importance of interleukin-6 in COVID-19.Lancet Respir. Med.202192e1310.1016/S2213‑2600(20)30600‑733460569
     [Google Scholar]
  3. WangX. TangG. LiuY. ZhangL. ChenB. HanY. FuZ. WangL. HuG. MaQ. ShengS. WangJ. HuX. ShaoS. The role of IL-6 in coronavirus, especially in COVID-19.Front. Pharmacol.202213103367410.3389/fphar.2022.103367436506506
     [Google Scholar]
  4. BineshA. DevarajS.N. HalagowderD. Molecular interaction of NFκB and NICD in monocyte–macrophage differentiation is a target for intervention in atherosclerosis.J. Cell. Physiol.201923457040705010.1002/jcp.2745830478968
     [Google Scholar]
  5. ShekhawatJ. GaubaK. GuptaS. PurohitP. MitraP. GargM. MisraS. SharmaP. BanerjeeM. Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm.Indian J. Clin. Biochem.202136444045010.1007/s12291‑021‑00989‑834177139
     [Google Scholar]
  6. RamanB. BluemkeD.A. LüscherT.F. NeubauerS. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.Eur. Heart J.202243111157117210.1093/eurheartj/ehac03135176758
     [Google Scholar]
  7. Rose-JohnS. Interleukin-6 signalling in health and disease.F1000Res20209F1000 Faculty Rev-101310.12688/f1000research.26058.132864098
     [Google Scholar]
  8. TanakaT. NarazakiM. KishimotoT. IL-6 in inflammation, immunity, and disease.Cold Spring Harb. Perspect. Biol.2014610a01629510.1101/cshperspect.a01629525190079
     [Google Scholar]
  9. YinJ.X. AgbanaY.L. SunZ.S. FeiS.W. ZhaoH.Q. ZhouX.N. ChenJ.H. KassegneK. Increased interleukin-6 is associated with long COVID-19: A systematic review and meta-analysis.Infect. Dis. Poverty20231214310.1186/s40249‑023‑01086‑z37095536
     [Google Scholar]
  10. BineshA. DevarajS.N. DevarajH. Expression of chemokines in macrophage polarization and downregulation of NFκB in aorta allow macrophage polarization by diosgenin in atherosclerosis.J. Biochem. Mol. Toxicol.2020342e2242210.1002/jbt.2242231729780
     [Google Scholar]
  11. GabayC. Interleukin-6 and chronic inflammation.Arthritis Res. Ther.20068Suppl 2), S3.(Suppl. 210.1186/ar191716899107
     [Google Scholar]
  12. Medina-LeyteD.J. Zepeda-GarcíaO. Domínguez-PérezM. González-GarridoA. Villarreal-MolinaT. Jacobo-AlbaveraL. Endothelial dysfunction, inflammation and coronary artery disease: Potential biomarkers and promising therapeutical approaches.Int. J. Mol. Sci.2021228385010.3390/ijms2208385033917744
     [Google Scholar]
  13. StarkK. MassbergS. Interplay between inflammation and thrombosis in cardiovascular pathology.Nat. Rev. Cardiol.202118966668210.1038/s41569‑021‑00552‑133958774
     [Google Scholar]
  14. AmbrosinoP. CalcaterraI.L. MosellaM. FormisanoR. D’AnnaS.E. BachettiT. MarcuccioG. GallowayB. ManciniF.P. PapaA. MottaA. Di MinnoM.N.D. ManiscalcoM. Endothelial dysfunction in COVID-19: A unifying mechanism and a potential therapeutic target.Biomedicines202210481210.3390/biomedicines1004081235453563
     [Google Scholar]
  15. MestasJ. LeyK. Monocyte-endothelial cell interactions in the development of atherosclerosis.Trends Cardiovasc. Med.200818622823210.1016/j.tcm.2008.11.00419185814
     [Google Scholar]
  16. BineshA. Devaraj SivasitambaramN. HalagowderD. Monocytes treated with ciprofloxacin and oxyLDL express myristate, priming atherosclerosis.J. Biochem. Mol. Toxicol.2020343e2244210.1002/jbt.2244231926051
     [Google Scholar]
  17. GagliardiM.C. TieriP. OrtonaE. RuggieriA. ACE2 expression and sex disparity in COVID-19.Cell Death Discov2020613710.1038/s41420‑020‑0276‑132499922
     [Google Scholar]
  18. PelleM.C. ZaffinaI. LucàS. ForteV. TrapaneseV. MelinaM. GiofrèF. ArturiF. Endothelial dysfunction in COVID-19: Potential mechanisms and possible therapeutic options.Life.20221210160510.3390/life1210160536295042
     [Google Scholar]
  19. MaruhashiT. HigashiY. Pathophysiological association of endothelial dysfunction with fatal outcome in COVID-19.Int. J. Mol. Sci.20212210513110.3390/ijms2210513134066226
     [Google Scholar]
  20. BineshA. DevarajS.N. DevarajH. Inhibition of nuclear translocation of notch intracellular domain (NICD) by diosgenin prevented atherosclerotic disease progression.Biochimie2018148637110.1016/j.biochi.2018.02.01129481959
     [Google Scholar]
  21. HasanS.S. KowC.S. HadiM.A. ZaidiS.T.R. MerchantH.A. Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: A systematic review and metaanalysis.Am J. Cardiovasc. Drugs202020657159010.1007/s40256‑020‑00439‑532918209
     [Google Scholar]
  22. CatanzaroM. FagianiF. RacchiM. CorsiniE. GovoniS. LanniC. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.Signal. Transduct Target Ther.2020518410.1038/s41392‑020‑0191‑132467561
     [Google Scholar]
  23. MerloC. BernardiE. BellottiF. PomidoriL. CogoA. Supervised exercise training improves endothelial function in COPD patients: A method to reduce cardiovascular risk?ERJ Open Res.20206200304201910.1183/23120541.00304‑201932714965
     [Google Scholar]
  24. LooJ. SpittleD.A. NewnhamM. COVID-19, immunothrombosis and venous thromboembolism: Biological mechanisms.Thorax202176441242010.1136/thoraxjnl‑2020‑21624333408195
     [Google Scholar]
  25. AnkaA.U. TahirM.I. AbubakarS.D. AlsabbaghM. ZianZ. HamedifarH. SabzevariA. AziziG. Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management.Scand. J. Immunol.2021934e1299810.1111/sji.1299833190302
     [Google Scholar]
  26. GiustinoG. PinneyS.P. LalaA. ReddyV.Y. Johnston-CoxH.A. MechanickJ.I. HalperinJ.L. FusterV. Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia.J. Am Coll Cardiol.202076172011202310.1016/j.jacc.2020.08.05933092737
     [Google Scholar]
  27. TangN. LiD. WangX. SunZ. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.J. Thromb. Haemost.202018484484710.1111/jth.1476832073213
     [Google Scholar]
  28. SammaritanoL.R. Antiphospholipid syndrome.Best Pract. Res. Clin. Rheumatol.202034110146310.1016/j.berh.2019.10146331866276
     [Google Scholar]
  29. Abdel-WahabN. TalathiS. Lopez-OlivoM.A. Suarez-AlmazorM.E. Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis.Lupus201827457258310.1177/096120331773153228945149
     [Google Scholar]
  30. KlokF.A. KruipM.J.H.A. van der MeerN.J.M. ArbousM.S. GommersD.A.M.P.J. KantK.M. KapteinF.H.J. van PaassenJ. StalsM.A.M. HuismanM.V. EndemanH. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb. Res.202019114514710.1016/j.thromres.2020.04.01332291094
     [Google Scholar]
  31. AsakuraH. OgawaH. COVID-19-associated coagulopathy and disseminated intravascular coagulation.Int. J. Hematol.20211131455710.1007/s12185‑020‑03029‑y33161508
     [Google Scholar]
  32. SuJ.H. LuoM.Y. LiangN. GongS.X. ChenW. HuangW.Q. TianY. WangA.P. Interleukin-6: A novel target for cardio-cerebrovascular diseases.Front Pharmacol.20211274506110.3389/fphar.2021.74506134504432
     [Google Scholar]
  33. GubernatorovaE.O. GorshkovaE.A. PolinovaA.I. DrutskayaM.S. IL-6: Relevance for immunopathology of SARS-CoV-2.Cytokine Growth Factor Rev.202053132410.1016/j.cytogfr.2020.05.00932475759
     [Google Scholar]
  34. DonatoA.J. MachinD.R. LesniewskiL.A. Mechanisms of dysfunction in the aging vasculature and role in age-related disease.Circ. Res.2018123782584810.1161/CIRCRESAHA.118.31256330355078
     [Google Scholar]
  35. BadimonL. PadróT. VilahurG. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease.Eur. Heart J. Acute Cardiovasc. Care201211607410.1177/204887261244158224062891
     [Google Scholar]
  36. TangY.H. VitalS. RussellJ. SeifertH. Neil GrangerD. Interleukin-6 mediates enhanced thrombus development in cerebral arterioles following a brief period of focal brain ischemia.Exp. Neurol.201527135135710.1016/j.expneurol.2015.06.00426054883
     [Google Scholar]
  37. TsigkouV. OikonomouE. AnastasiouA. LampsasS. ZakynthinosG.E. KalogerasK. KatsioupaM. KapsaliM. KourampiI. PesiridisT. MarinosG. VavuranakisM.A. TousoulisD. VavuranakisM. SiasosG. Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure.Int. J. Mol. Sci.2023245432110.3390/ijms2405432136901752
     [Google Scholar]
  38. ChiaY.C. KienekerL.M. van HasselG. BinnenmarsS.H. NolteI.M. van ZandenJ.J. van der MeerP. NavisG. VoorsA.A. BakkerS.J.L. De BorstM.H. EisengaM.F. Interleukin 6 and development of heart failure with preserved ejection fraction in the general population.J. Am Heart Assoc20211011e01854910.1161/JAHA.120.01854933998283
     [Google Scholar]
  39. SchneiderM. The role of biomarkers in hospitalized COVID-19 patients with systemic manifestations.Biomark. Insights2022171177271922110890910.1177/1177271922110890935783222
     [Google Scholar]
  40. EsmailianM. VakiliZ. Nasr-EsfahaniM. HeydariF. MasoumiB. D-dimer levels in predicting severity of infection and outcome in patients with COVID-19.Tanaffos202221441943337583776
     [Google Scholar]
  41. HolderS.M. BrunoR.M. ShkredovaD.A. DawsonE.A. JonesH. HopkinsN.D. HopmanM.T.E. BaileyT.G. CoombesJ.S. AskewC.D. NaylorL. MaioranaA. GhiadoniL. ThompsonA. GreenD.J. ThijssenD.H.J. Reference intervals for brachial artery flow-mediated dilation and the relation with cardiovascular risk factors.Hypertension20217751469148010.1161/HYPERTENSIONAHA.120.1575433745297
     [Google Scholar]
  42. ChanK.H. PatelB. PodelB. SzableaM.E. ShaabanH.S. GuronG. SlimJ. Tocilizumab and thromboembolism in COVID-19: A retrospective hospital-based cohort analysis.Cureus2021135e1520810.7759/cureus.1520834178527
     [Google Scholar]
  43. LuoY. YaoF. ShiY. ZhuZ. XiaoZ. YouX. LiuY. YuS. TianD. ChengL. ZhengM. JingJ. Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells.Fluids Barriers CNS2023201110.1186/s12987‑022‑00399‑936624478
     [Google Scholar]
  44. Al-SamkariH. Karp LeafR.S. DzikW.H. CarlsonJ.C.T. FogertyA.E. WaheedA. GoodarziK. BendapudiP.K. BornikovaL. GuptaS. LeafD.E. KuterD.J. RosovskyR.P. COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection.Blood2020136448950010.1182/blood.202000652032492712
     [Google Scholar]
  45. MaL. WilleyJ. The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.Thrombosis Update2022810011710.1016/j.tru.2022.10011738620713
     [Google Scholar]
  46. KusumawardhaniN.Y. PutraI.C.S. KamarullahW. AfriantiR. PramudyoM. IqbalM. PrameswariH.S. AchmadC. TiksnadiB.B. AkbarM.R. Cardiovascular disease in post-acute COVID-19 syndrome: A comprehensive review of pathophysiology and diagnosis approach.Rev. Cardiovasc Med.20232412810.31083/j.rcm240102839076856
     [Google Scholar]
  47. DuP. GengJ. WangF. ChenX. HuangZ. WangY. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.Int. J. Med. Sci.20211861356136210.7150/ijms.5356433628091
     [Google Scholar]
  48. MosterM. BolligerD. Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update.Curr. Anesthesiol. Rep202212228629610.1007/s40140‑021‑00511‑z
     [Google Scholar]
  49. MalikA. HaN.B. BarnesG.D. Choice and duration of anticoagulation for venous thromboembolism.J. Clin. Med.202413130110.3390/jcm1301030138202308
     [Google Scholar]
/content/journals/chddt/10.2174/011871529X371965250618060805
Loading
IL 6 Cascade in Post COVID Cardiovascular Complications: A Review of Endothelial Injury and Clotting Pathways
Cardiovasc Hematol Disord Drug Targets 25, 149 (2025); https://doi.org/10.2174/011871529X371965250618060805
/content/journals/chddt/10.2174/011871529X371965250618060805
/content/journals/chddt/10.2174/011871529X371965250618060805
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): endothelial dysfunction; IL-6 inhibitors; interleukin-6; novel therapeutics; Post-COVID cardiovascular issues; thrombotic events

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test